<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483743</url>
  </required_header>
  <id_info>
    <org_study_id>TPI 1020-203</org_study_id>
    <nct_id>NCT00483743</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients</brief_title>
  <official_title>Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess and compare the safety and tolerability of inhaled TPI 1020 (repeated
      nominal doses; 500 μg BID x 6 weeks) versus inhaled budesonide (repeated doses; 800 μg BID x
      6 weeks) and a matching placebo. Pharmacodynamic (PD) activity on FEV1, sputum and blood
      cells and cytokines will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre, randomized, placebo and active-controlled, 6-week study of inhaled TPI 1020,
      inhaled budesonide or matching placebo (random allocation of eligible patients to the three
      treatments at a ratio of 3:3:1), to evaluate the safety, tolerability and pharmacodynamic
      activity of TPI 1020 in 42 evaluable COPD subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the airway specific, and general safety and the tolerability of inhaled TPI 1020 administered via Aerolizer™ in COPD patients. • To assess the effects of TPI 1020 versus those of budesonide on sputum neutrophil counts on Days 0 and 42.</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum neutrophil counts on Days 0 and 21. • Trough FEV1, SVC and IC on Days 0, 21 and on Day 42. • eNO levels on Days 0, 21 and on Day 42.</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Copd Bronchitis</condition>
  <arm_group>
    <arm_group_label>TPI 1020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI 1020 500 mcg BID x 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budosenide cortico</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide 800 mcg BID x 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI 1020</intervention_name>
    <description>250 mcg/caps 2 caps BID x 42 days</description>
    <arm_group_label>TPI 1020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>400mcg mcg capsules- 2 capsules BID</description>
    <arm_group_label>Budosenide cortico</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 caps BID x42 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients, male or female, smoker or ex-smoker (who quit at least a year ago) with a
             smoking history equal or greater than 10 pack years.

          -  Age between 40 and 80 years old with a diagnosis (for at least 12 months) of mild to
             moderate COPD

        Exclusion Criteria:

          -  COPD exacerbations indicated by a treatment with oral or systemic glucocorticosteroids
             and/or hospitalization and/or clinically relevant respiratory infection requiring
             antibiotics within 3 month of the start of the study.

          -  Failure to produce a sufficient sputum sample during the screening sputum induction
             procedure, required for TCC and differential cell count determination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Maltais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Cardiologie et de Pneumologie de l'Université Laval</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rene Pageau, M.Sc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaxis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of alberta Hsopital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Hospital Lung Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1 M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Firestone Institute for Respiratory Health</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medical Les Saules</name>
      <address>
        <city>Les Saules</city>
        <state>Quebec</state>
        <zip>G1P 1J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omnispec Clinical Research Inc.</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Thoracique Montreal-CSUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kells Medical Research Group</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS -Hopital FLEURIMONT</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexe Medicale Langelier</name>
      <address>
        <city>St-Leonard</city>
        <state>Quebec</state>
        <zip>H1S 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Cardiologie et de Pneumologie de l'Université Laval</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

